Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to < 18 years of age, with HSCT-TMA. The treatment period is 26 weeks, followed by a 26-week off-treatment follow-up period.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04557735
Study type Interventional
Source Alexion Pharmaceuticals, Inc.
Contact Alexion Pharmaceuticals Inc.
Phone 855-752-2356
Status Recruiting
Phase Phase 3
Start date November 6, 2020
Completion date June 30, 2025

See also
  Status Clinical Trial Phase
Completed NCT02604420 - Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants
Terminated NCT04743804 - Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger Phase 3
Recruiting NCT04845022 - Incidence of Snakebite Associated Thrombotic Microangiopathy & Role of Peripheral Blood Smear as a Predictor of Clinical Outcome
Terminated NCT00593229 - International Registry and Biorepository for TMA(Thrombotic Microangiopathy) N/A
Recruiting NCT05991245 - French National Cohort MATRIX "Renal and Systemic Thrombotic Microangiopathy"
Terminated NCT00726544 - Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy Phase 2
Recruiting NCT04543591 - Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant Phase 3
Available NCT02355782 - OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy N/A